July 24, 2019
GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update
Media
July 23, 2019
MIPS INTERIM REPORT JANUARY – JUNE 2019
July 16, 2019
Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
July 12, 2019
GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule
July 11, 2019
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)
July 11, 2019
Orexo Interim Report Q2 2019
July 10, 2019
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
July 10, 2019
Orexo prepays part of the corporate bond loan
July 10, 2019
MIPS APPOINTS NEW CFO
July 09, 2019
Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma